source
- China aims for 25% of global first-in-class drugs by 2030 under new five-year planChina's government has set an ambitious target to capture at least a quarter of the world’s first‑in‑class drug discoveries by 2030. The goal is part of a five‑year plan released by the National Me…
- Experts see Replimune’s Tudriqev approval as a step toward broader use of localized cancer therapiesReplimune received FDA approval last month for Tudriqev, an oncolytic virus injected directly into melanoma tumors, marking only the second such approval for a therapy delivered straight into a tum…